ImmunityBio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 14, 2022, details the results of ImmunityBio, Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol IBRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Approximately 90% of the 397,953,809 outstanding shares were represented at the meeting, establishing a quorum. Three primary matters were voted upon:
- Election of Directors: All nine nominees were re-elected for one-year terms. Patrick Soon-Shiong, M.D., received the highest number of "For" votes (330,988,601), while Richard Adcock received the fewest "Withheld" votes (1,980,129).
- Equity Incentive Plan Amendment: Stockholders approved an amendment to increase the number of shares authorized for issuance under the 2015 Equity Incentive Plan by 19,900,000 shares. The vote was 323,063,732 "For" versus 16,456,591 "Against."
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 358,682,234 "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote tallies.
Key Facts for Investor Verification
- Confirmation that the 19,900,000 share increase to the 2015 Equity Incentive Plan has been formally implemented in the company's capital structure.
- Verification of the re-election terms for the nine directors, which expire at the 2023 annual meeting.
- Confirmation that Ernst & Young LLP is officially engaged as the auditor for the fiscal year ending December 31, 2022.
- Review of the "Withheld" vote percentages for directors to assess shareholder sentiment regarding specific board members.